Trials / Withdrawn
WithdrawnNCT04301310
Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants
A Phase 1, Open-label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety, and Tolerability of BMS-986235 in Healthy Participants
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to examine the effect of rifampin on the drug levels in blood and safety of BMS-986235, when taken by healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986235 (Treatment A) | Specified dose on specified days |
| DRUG | Rifampin (Treatment B) | Specified dose on specified days |
Timeline
- Start date
- 2020-03-09
- Primary completion
- 2020-03-16
- Completion
- 2020-03-16
- First posted
- 2020-03-10
- Last updated
- 2022-03-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04301310. Inclusion in this directory is not an endorsement.